RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Biocartis Group Stock

Biocartis Group Stocks 2024

Biocartis Group Stocks

60.55 M

Ticker

BCART.BR

ISIN

BE0974281132

WKN

A14R82

In 2024, Biocartis Group had 60.55 M outstanding stocks, a 0% change from the 60.55 M stocks in the previous year.

The Biocartis Group Stocks history

YEARNUMBER OF STOCKS (undefined EUR)
2025e60.55
2024e60.55
2023e60.55
202260.55
202165.97
202064.9
201964.28
201858.66
201751.76
201647.03
201537.06
201425.52
201325.52
201225.52

Biocartis Group shares outstanding

The number of shares was Biocartis Group in 2023 — This indicates how many shares 60.546 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biocartis Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biocartis Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biocartis Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biocartis Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biocartis Group Aktienanalyse

What does Biocartis Group do?

Biocartis Group NV is a Belgian biotechnology company specializing in the development and marketing of innovative diagnostic test systems. The company was founded in 2007 and is headquartered in Mechelen, Belgium. Biocartis focuses on various disease areas such as gynecology, oncology, infectious diseases, and immunology. Biocartis' business model is based on a unique diagnostic test system called Idylla, which allows for rapid testing within hours instead of the usual weeks. The Idylla platform also offers high accuracy in identifying biomarkers and easy handling for medical personnel. The company has certified distribution partners worldwide to support the marketing and sales of Biocartis products. Biocartis collaborates closely with pharmaceutical companies, medical laboratories, and clinics globally to deliver the best results for its customers. The company also has partnerships with other biotech companies like Merck and Genomic Health to support the development of its diagnostic tests. Biocartis offers a wide range of diagnostic tests for various cancer types, gynecology, and infectious diseases. Their tests help physicians identify the type and extent of tumors and monitor patients' health status. Through the development and marketing of innovative diagnostic test systems, Biocartis aims to improve disease diagnosis and monitoring, ultimately enhancing treatment for patients worldwide. Overall, Biocartis is a leading company in the biotechnology industry specializing in the development and marketing of innovative diagnostic test systems for various disease areas. With its certified distribution partners and partnerships with other biotech companies, Biocartis has a strong presence in the global market and is well positioned to continue being a key player in the biomedical diagnostics industry. Biocartis Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Biocartis Group's Shares Outstanding

Biocartis Group's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Biocartis Group’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Biocartis Group’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Biocartis Group’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Biocartis Group stock

How many stocks are there of Biocartis Group?

The current number of stocks of Biocartis Group is 60.55 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Biocartis Group are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Biocartis Group evolved in recent years?

The number of shares of Biocartis Group has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Biocartis Group as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Biocartis Group?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Biocartis Group pay?

Over the past 12 months, Biocartis Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biocartis Group is expected to pay a dividend of 0 EUR.

What is the dividend yield of Biocartis Group?

The current dividend yield of Biocartis Group is .

When does Biocartis Group pay dividends?

Biocartis Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biocartis Group?

Biocartis Group paid dividends every year for the past 0 years.

What is the dividend of Biocartis Group?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biocartis Group located?

Biocartis Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biocartis Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biocartis Group from 12/4/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did Biocartis Group pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of Biocartis Group in the year 2023?

In the year 2023, Biocartis Group distributed 0 EUR as dividends.

In which currency does Biocartis Group pay out the dividend?

The dividends of Biocartis Group are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Biocartis Group

Our stock analysis for Biocartis Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocartis Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.